CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma

Cancer Letters

Volumn 378, Issue 1, 2016, Pages 16-22

  Matsuo, Kazuhiko ^a   Itoh, Tatsuki ^a   Koyama, Atsushi ^a   Imamura, Reira ^a   Kawai, Shiori ^a   Nishiwaki, Keiji ^a   Oiso, Naoki ^b   Kawada, Akira ^b   Yoshie, Osamu ^b   Nakayama, Takashi ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CCR4; Chemokine; Melanoma; Th17; Treg

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR4 ANTAGONIST; CHEMOKINE RECEPTOR CCR6; COMPOUND 22; DACARBAZINE; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 17; MACROPHAGE DERIVED CHEMOKINE; UNCLASSIFIED DRUG; ALKYLATING AGENT; CCL22 PROTEIN, MOUSE; CCR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; INOCULATION; LYMPH NODE; MELANOMA B16; MELANOMA CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH17 CELL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DEFICIENCY; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; GENOTYPE; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL22; DACARBAZINE; DENDRITIC CELLS; GENOTYPE; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; RECEPTORS, CCR4; SIGNAL TRANSDUCTION; TH17 CELLS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84966311092     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.04.039     Document Type: Article

References (38)

1. Imai T., Baba M., Nishimura M., Kakizaki M., Takagi S., Yoshie O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J. Biol. Chem 1997, 272:15036-15042.
2. Imai T., Chantry D., Raport C.J., Wood C.L., Nishimura M., Godiska R., et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J. Biol. Chem 1998, 273:1764-1768.
3. Imai T., Nagira M., Takagi S., Kakizaki M., Nishimura M., Wang J., et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol 1999, 11:81-88.
4. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med 2004, 10:942-949.
5. Lim H.W., Lee J., Hillsamer P., Kim C.H. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J. Immunol 2008, 180:122-129.
6. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest 2009, 119:3573-3585.
7. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
8. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
9. Watanabe Y., Katou F., Ohtani H., Nakayama T., Yoshie O., Hashimoto K. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod 2010, 109:744-752.
10. Jones E., Dahm-Vicker M., Simon A.K., Green A., Powrie F., Cerundolo V., et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002, 2:1.
11. Pere H., Montier Y., Bayry J., Quintin-Colonna F., Merillon N., Dransart E., et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011, 118:4853-4862.
12. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med 2005, 201:233-240.
13. Leipe J., Grunke M., Dechant C., Reindl C., Kerzendorf U., Schulze-Koops H., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2012, 62:2876-2885.
14. Feng T., Qin H., Wang L., Benveniste E.N., Elson C.O., Cong Y. Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production. J. Immunol 2011, 186:6313-6318.
15. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
16. Ankathatti Munegowda M., Deng Y., Mulligan S.J., Xiang J. Th17 and Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol. Immunother 2011, 60:1473-1484.
17. Purandare A.V., Wan H., Somerville J.E., Burke C., Vaccaro W., Yang X., et al. Core exploration in optimization of chemokine receptor CCR4 antagonists. Bioorg. Med. Chem. Lett 2007, 17:679-682.
18. Yoshida T., Izawa D., Nakayama T., Nakahara K., Kakizaki M., Imai T., et al. Molecular cloning of mXCR1, the murine SCM-1/lymphotactin receptor. FEBS Lett 1999, 458:37-40.
19. Reiss Y., Proudfoot A.E., Power C.A., Campbell J.J., Butcher E.C. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med 2001, 194:1541-1547.
20. Tubo N.J., McLachlan J.B., Campbell J.J. Chemokine receptor requirements for epidermal T-cell trafficking. Am. J. Pathol 2011, 178:2496-2503.
21. Aspord C., Leccia M.T., Charles J., Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol. Res 2013, 1:402-415.
22. Xia S., Wei J., Wang J., Sun H., Zheng W., Li Y., et al. A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells. J. Leukoc. Biol 2014, 95:733-742.
23. Alferink J., Lieberam I., Reindl W., Behrens A., Weiss S., Huser N., et al. Compartmentalized production of CCL17 in vivo: strong inducibility in peripheral dendritic cells contrasts selective absence from the spleen. J. Exp. Med 2003, 197:585-599.
24. Katou F., Ohtani H., Nakayama T., Ono K., Matsushima K., Saaristo A., et al. Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am. J. Pathol 2001, 158:1263-1270.
25. Medoff B.D., Seung E., Hong S., Thomas S.Y., Sandall B.P., Duffield J.S., et al. CD11b+ myeloid cells are the key mediators of Th2 cell homing into the airway in allergic inflammation. J. Immunol 2009, 182:623-635.
26. Kaminuma O., Ohtomo T., Mori A., Nagakubo D., Hieshima K., Ohmachi Y., et al. Selective down-regulation of Th2 cell-mediated airway inflammation in mice by pharmacological intervention of CCR4. Clin. Exp. Allergy 2012, 42:315-325.
27. Chizzolini C., Chicheportiche R., Alvarez M., de Rham C., Roux-Lombard P., Ferrari-Lacraz S., et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008, 112:3696-3703.
28. Huber S., Schramm C., Lehr H.A., Mann A., Schmitt S., Becker C., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol 2004, 173:6526-6531.
29. Zheng S.G., Wang J., Wang P., Gray J.D., Horwitz D.A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol 2007, 178:2018-2027.
30. Kondo T., Takiguchi M. Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines. Int. Immunol 2009, 21:523-532.
31. Mullins I.M., Slingluff C.L., Lee J.K., Garbee C.F., Shu J., Anderson S.G., et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004, 64:7697-7701.
32. Eggermont A.M., Spatz A., Robert C. Cutaneous melanoma. Lancet 2014, 383:816-827.
33. Nakayama T., Hieshima K., Arao T., Jin Z., Nagakubo D., Shirakawa A.K., et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene 2008, 27:3221-3232.
34. Higuchi T., Nakayama T., Arao T., Nishio K., Yoshie O. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Blood 2013, 121:3640-3649.
35. Yamamoto K., Utsunomiya A., Tobinai K., Tsukasaki K., Uike N., Uozumi K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol 2010, 28:1591-1598.
36. Ishida T., Joh T., Uike N., Yamamoto K., Utsunomiya A., Yoshida S., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol 2012, 30:837-842.
37. Sugiyama D., Nishikawa H., Maeda Y., Nishioka M., Tanemura A., Katayama I., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:17945-17950.
38. Kurose K., Ohue Y., Wada H., Iida S., Ishida T., Kojima T., et al. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. Clin. Cancer Res 2015, 21:4327-4336.